RankAlpha logo
Back to Rankings

TSHA

Taysha Gene TherapiesD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-11
View Chart
Current thesis
Positive clinical readouts or a partnership deal that materially extends runway would validate Taysha's CNS program value and could drive a strong rerating toward the bull target; modest near-term dilution risk would be offset by de-risking milestones.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -24.0.
What can break
Failure to secure financing before mid-2026 or disappointing clinical data would likely cause a deep drawdown toward the bear target; limited near-term revenue and binary program outcomes amplify downside.
Momentum
50
Value
41
Sentiment
43
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.50 · Bull $8.00 · Bear $3.00
Data freshness
Prices
As of 2026-06-11
Fundamentals
As of 2026-06-11 • Vendor: Data Vendor v1
Scores
As of 2026-06-11 • Model: HYBRID_IC_RP
AI Memo
As of 2025-12-06 • Model: RankAlpha Sentiment AI
Investment thesis
As of 2026-06-11
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $11.00
Why
Momentum50 · Δ7d -24.0
Value41 · Δ7d -0.1
Sentiment43 · Δ7d -1.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
50
34% active weight
Current posture
7d trendSoftening
Δ7d
-24.0
Δ21d
-48.4
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.1
Sentiment
43
33% active weight
Current posture
7d trendSoftening
Δ7d
-1.4
Δ21d
+1.4
Why this grade

Composite grade D. Momentum 49.7 / Value 41.0 / Sentiment 42.5

Fundamentals (TTM)
As of 2026-06-11
Market Cap
$1.6B
Beta
0.99
Shares Out
273.92M
P/E (TTM) · Derived
-16.3
P/S (TTM)
212.28
P/FCF (TTM) · Derived
-20.43
Rev YoY
-100.0%
EPS YoY
+2.8%
Gross Margin
-
Op Margin
-1618.5%
Net Debt
-$94.32M
Current Ratio
10.48
As of 2026-06-11 • Updated nightlySource: Internal modelMethodology